Lixte Biotechnology Holdings Stock Performance
| LIXT Stock | USD 1.63 0.11 7.24% |
The company secures a Beta (Market Risk) of -0.86, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Lixte Biotechnology are expected to decrease slowly. On the other hand, during market turmoil, Lixte Biotechnology is expected to outperform it slightly. Lixte Biotechnology right now secures a risk of 9.02%. Please verify Lixte Biotechnology Holdings treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to decide if Lixte Biotechnology Holdings will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lixte Biotechnology Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Lixte Biotechnology is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Last Split Factor 1:10 | Dividend Date 2020-11-20 | Last Split Date 2023-06-05 |
1 | LIXT - Lixte Biotechnology Holdings, Inc. Latest Stock News Market Updates - StockTitan | 09/04/2024 |
2 | Acquisition by Forman Eric of 1112 shares of Lixte Biotechnology at 0.63 subject to Rule 16b-3 | 10/04/2024 |
3 | Acquisition by Forman Eric of 6059 shares of Lixte Biotechnology at 0.5593 subject to Rule 16b-3 | 11/15/2024 |
4 | Acquisition by Van Der Baan Bastiaan Jeroen of 10000 shares of Lixte Biotechnology at 5.88 subject to Rule 16b-3 | 11/18/2024 |
| Begin Period Cash Flow | 5.4 M |
Lixte |
Lixte Biotechnology Relative Risk vs. Return Landscape
If you would invest 200.00 in Lixte Biotechnology Holdings on August 25, 2024 and sell it today you would lose (37.00) from holding Lixte Biotechnology Holdings or give up 18.5% of portfolio value over 90 days. Lixte Biotechnology Holdings is currently generating 0.0148% in daily expected returns and assumes 9.0195% risk (volatility on return distribution) over the 90 days horizon. In different words, 80% of stocks are less volatile than Lixte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lixte Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lixte Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lixte Biotechnology Holdings, and traders can use it to determine the average amount a Lixte Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0016
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LIXT |
Estimated Market Risk
| 9.02 actual daily | 80 80% of assets are less volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lixte Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lixte Biotechnology by adding Lixte Biotechnology to a well-diversified portfolio.
Lixte Biotechnology Fundamentals Growth
Lixte Stock prices reflect investors' perceptions of the future prospects and financial health of Lixte Biotechnology, and Lixte Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lixte Stock performance.
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.87 | ||||
| Current Valuation | 5.21 M | ||||
| Shares Outstanding | 2.25 M | ||||
| Price To Earning | (2.96) X | ||||
| Price To Book | 12.00 X | ||||
| EBITDA | 3.21 K | ||||
| Net Income | (5.09 M) | ||||
| Cash And Equivalents | 7.74 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 313.86 K | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.10 X | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (4.29 M) | ||||
| Earnings Per Share | (1.73) X | ||||
| Market Capitalization | 3.42 M | ||||
| Total Asset | 4.31 M | ||||
| Retained Earnings | (48.48 M) | ||||
| Working Capital | 3.99 M | ||||
| Current Asset | 1.38 M | ||||
| Current Liabilities | 140 K | ||||
About Lixte Biotechnology Performance
Assessing Lixte Biotechnology's fundamental ratios provides investors with valuable insights into Lixte Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Lixte Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.18) | (1.24) | |
| Return On Capital Employed | (1.27) | (1.34) | |
| Return On Assets | (1.18) | (1.24) | |
| Return On Equity | (1.27) | (1.34) |
Things to note about Lixte Biotechnology performance evaluation
Checking the ongoing alerts about Lixte Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lixte Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lixte Biotechnology had very high historical volatility over the last 90 days | |
| Lixte Biotechnology may become a speculative penny stock | |
| Lixte Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.09 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lixte Biotechnology Holdings currently holds about 7.74 M in cash with (4.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Lixte Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Van Der Baan Bastiaan Jeroen of 10000 shares of Lixte Biotechnology at 5.88 subject to Rule 16b-3 |
- Analyzing Lixte Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lixte Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Lixte Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lixte Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lixte Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lixte Biotechnology's stock. These opinions can provide insight into Lixte Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.